CD107a is a protein that sits on the inner membranes of immune cells and temporarily appears on their outer surface when those cells attack a target, making it one of the most widely used laboratory markers for measuring whether killer immune cells are actually doing their job. Formally known as lysosome-associated membrane protein 1 (LAMP-1), it spends most of its time lining tiny sacs called lysosomes inside the cell, with only about one to two percent of the total protein found on the outer membrane at rest. The reason immunologists care about it so much is simple: when a natural killer cell or a cytotoxic T cell fires its lethal cargo at a virus-infected or cancerous cell, CD107a gets dragged to the surface in the process, and researchers can catch it there with a fluorescent antibody. That flash of surface CD107a has become a go-to readout in everything from diagnosing rare genetic diseases to evaluating experimental cancer therapies.
How CD107a Ends Up on the Cell Surface
Inside a resting immune cell, CD107a lines the membranes of lysosomes and related compartments. These organelles store the cell’s killing machinery, including proteins like perforin and granzyme B that punch holes in target cells and trigger their death. When the immune cell recognizes something it needs to destroy, those granules travel along internal tracks toward the point of contact, known as the immunological synapse. The granule membranes then fuse with the cell’s outer membrane, dumping perforin and granzymes into the narrow space between killer and target. Because CD107a is embedded in those granule membranes, it gets swept onto the cell surface during this fusion event.
The process depends on calcium. Research on human T cells has shown that the surface appearance of CD107a and the release of granzyme B both require extracellular calcium, while other killing molecules like FasL can move to the surface without it. The two pathways also respond differently to drugs that interfere with the cell’s internal skeleton: blocking actin polymerization actually increases CD107a mobilization, while inhibiting a motor protein called myosin 2a impairs it. These findings confirm that CD107a reaches the surface through a specific transport route tied to granule exocytosis, not through some generic membrane reshuffling.
Why It Became the Standard Degranulation Readout
Before CD107a assays, the main way to measure the killing power of natural killer cells was the chromium-release assay, which involved loading target cells with radioactive chromium and then seeing how much leaked out after the killer cells attacked. It worked, but it was cumbersome, required radioactive materials, and told you nothing about which individual cells did the killing. CD107a changed the game because it could be detected on individual cells using flow cytometry, a technique that sorts and analyzes thousands of cells per second by their fluorescent labels.
A landmark paper in the Journal of Immunological Methods established CD107a as a functional marker for NK cell activity, showing that its surface expression correlated with both cytokine secretion and direct killing of target cells. Around the same time, separate work demonstrated that CD107a-positive CD8+ T cells mediate killing in an antigen-specific manner, and that the CD107a assay could be combined with other staining techniques to build a more complete picture of T cell function. Together, these studies made CD107a the default readout for degranulation in both innate and adaptive killer cells.
How the Assay Actually Works
The basic setup is straightforward. Researchers isolate immune cells from a patient’s blood and mix them with target cells, often a leukemia cell line called K562 that NK cells naturally recognize and attack. Crucially, a fluorescently labeled antibody against CD107a is added to the culture medium at the start of the incubation, not after it. This matters because CD107a does not stay on the surface for long. Once exposed, it gets pulled back inside the cell through endocytosis, and the brief window would be easy to miss if you stained afterward. By having the antibody present throughout the incubation, it binds CD107a the moment it appears, and even as the complex is internalized, the fluorescent tag stays attached. A chemical called monensin is often added to prevent degradation of the internalized antibody-CD107a complexes, further boosting the signal.
After a few hours of co-incubation, the cells are stained with additional markers to identify specific populations, then run through a flow cytometer. The percentage of NK cells or T cells that are CD107a-positive gives a direct measure of how many cells degranulated. Protocols vary in incubation length. A recent study comparing 6-hour and 18-hour stimulation periods found both can work in a clinical immunology lab, offering flexibility depending on workflow needs. More sophisticated approaches now use differentially labeled anti-CD107a antibodies added at successive time points, allowing researchers to identify NK cells that degranulate repeatedly against serial targets rather than just once.
Diagnosing Genetic Immune Disorders
One of the most impactful clinical applications of CD107a testing is in the diagnosis of primary hemophagocytic lymphohistiocytosis, a group of inherited conditions in which the immune system’s kill switch is broken. Patients with these disorders carry mutations in genes encoding proteins needed for granule transport and membrane fusion. Because their killer cells cannot properly release their granules, CD107a never reaches the surface in normal amounts.
A large retrospective study of over 1,600 patients referred for evaluation found that measuring CD107a upregulation on NK cells had a sensitivity of about 94% for detecting patients with disease-causing mutations in the relevant degranulation genes. That handily outperformed the older NK cell cytotoxicity assay, which caught only about 60% of affected patients. A pan-European study found even higher sensitivity, with 96% of patients with familial HLH and related disorders showing fewer than 5% CD107a-positive NK cells after stimulation. The practical implication is significant: in a child with unexplained fevers, enlarged spleen, and abnormal blood counts, a CD107a degranulation test can rapidly narrow the differential diagnosis and flag patients who need urgent treatment, including potentially life-saving bone marrow transplant.
Evaluating Cancer Immunotherapies
The rise of engineered immune cell therapies has given CD107a a second life in clinical research. CAR T-cell therapy, which involves genetically modifying a patient’s T cells to recognize and attack their cancer, depends on those cells actually degranulating when they encounter tumor cells. CD107a assays provide a quick functional check. In a typical setup, CAR T cells are co-cultured with the tumor cells they were designed to target, and a fluorescent anti-CD107a antibody is present in the medium during the incubation. If the CAR T cells recognize and attack the target, they degranulate and light up with the CD107a signal.
This has become a standard quality-control step during the development of new CAR T-cell products. Researchers can test whether a new CAR construct triggers degranulation against the intended target, whether specificity holds in the presence of bystander cells, and whether bispecific antibody platforms can redirect CAR T cells to new targets. The assay is fast, usually requiring only a few hours of co-culture, and pairs naturally with other readouts like cytokine production and direct killing measurements.
CD107a in Viral Infections
Chronic viral infections put prolonged stress on the immune system, and CD107a has become a useful window into how killer cells cope or fail to cope over time. In HIV infection, research has shown that CD107a expression on CD8+ T cells is negatively correlated with markers of immune exhaustion, such as PD-1, and with systemic inflammation. In other words, the more exhausted and burned out a T cell becomes, the less capable it is of degranulating. Even in patients on effective antiretroviral therapy with undetectable viral loads, this altered cytotoxic program persists, suggesting that immune exhaustion leaves a lasting imprint on killer cell function. Monitoring CD107a alongside exhaustion markers like PD-1, TIM-3, and LAG-3 gives clinicians and researchers a way to assess how functionally competent a patient’s T cells remain.
COVID-19 research has also drawn on CD107a. A study comparing children and adults with the disease found that NK cells in pediatric patients showed more robust cytotoxicity, with richer expression of cytotoxic molecules and upregulated killing pathways. CD107a degranulation assays confirmed this age-related difference, adding evidence that the more vigorous innate immune response in children partly explains their generally milder disease course.
Beyond Immune Killing
Because LAMP-1 is fundamentally a lysosomal protein, its relevance extends beyond immune cells. Lysosomes are the recycling centers of every cell in the body, breaking down worn-out proteins, damaged organelles, and engulfed material. LAMP-1 helps protect the lysosomal membrane from being digested by its own enzymes, and it participates in the fusion events that allow lysosomes to merge with other compartments. This means CD107a/LAMP-1 shows up in contexts that have nothing to do with immune killing.
One important caveat discovered in neuroscience research is that LAMP-1 is not as specific a lysosome marker as many assumed. A study in the nervous system demonstrated that a significant portion of LAMP-1-labeled organelles actually lack the major enzymes that define a true lysosome. In other words, just because an organelle is LAMP-1-positive does not necessarily mean it is a functional degradation compartment. This finding matters for any researcher using LAMP-1 staining to track lysosomes in experiments, because some of those “lysosomes” are really endosomes or other intermediary structures.
Pathogens That Exploit LAMP-1
Some bacteria have evolved strategies to hijack LAMP-1 for their own survival. Salmonella is a striking example. After being engulfed by a host cell, the bacterium ends up inside a compartment called the Salmonella-containing phagosome. Normally, this compartment would fuse with lysosomes and the bacterium would be destroyed. But Salmonella secretes a protein called SipC that binds to a host protein called Syntaxin6, redirecting traffic from the Golgi apparatus to deliver LAMP-1-containing vesicles to the bacterial compartment. By acquiring LAMP-1, the Salmonella-containing phagosome mimics a late endosome and avoids the destructive lysosomal enzymes that would kill the bacterium. This molecular sleight-of-hand turns a host defense protein into a survival tool for the pathogen.
LAMP-1 in Alzheimer’s Disease
Changes in the lysosomal system are among the earliest cellular abnormalities seen in Alzheimer’s disease, and LAMP-1 is caught up in those changes. Studies of postmortem brain tissue have found that LAMP-1 messenger RNA and protein are both upregulated in the cerebral cortex of patients with Alzheimer’s, with increased staining visible in neurons and in the glial cells surrounding amyloid plaques. This supports the idea that lysosomes are actively involved in trying to clear amyloid-beta and hyperphosphorylated tau, the two hallmark proteins of the disease, and that the lysosomal system ramps up production of its membrane proteins in response to the rising workload.
Separate work measuring proteins in cerebrospinal fluid found that LAMP-1 levels were significantly elevated in Alzheimer’s patients compared with neurological controls. The same study identified several other lysosomal network proteins that were similarly elevated, including LAMP-2 and markers of autophagy and endosomal trafficking. These increases appeared specific to Alzheimer’s rather than reflecting general brain damage, raising the possibility that LAMP-1 in spinal fluid could eventually serve as a biomarker for the disease, though that application remains in the research phase.
Soluble LAMP-1 as a Blood Biomarker
LAMP-1 is not limited to cell surfaces and organelle membranes. A soluble form circulates in the blood, shed from activated cells. Recent research in systemic lupus erythematosus has found that soluble LAMP-1 is significantly elevated in the serum of lupus patients compared with healthy controls, with the highest levels appearing in patients with proliferative lupus nephritis, the most dangerous form of kidney involvement. The same study identified LAMP-1 as a marker of neutrophil activation in lupus and flagged both serum and urinary LAMP-1 as potential noninvasive biomarkers for proliferative kidney disease. If validated in larger cohorts, measuring soluble LAMP-1 with a simple blood or urine test could help rheumatologists gauge kidney involvement without requiring a biopsy.
Limitations Worth Knowing About
CD107a is a powerful tool, but it has quirks that can trip up researchers who treat it as a simple on-off switch for killing. The biggest technical challenge is that rapid re-internalization issue: once CD107a pops up on the cell surface, it gets pulled back inside within minutes. If the fluorescent antibody is not present during stimulation, the signal gets dramatically underestimated. Adding monensin helps by blocking degradation of internalized complexes, but the assay design still needs to account for this recycling. Protocols that stain only after co-culture, rather than during it, will consistently undercount degranulating cells.
Biologically, degranulation and killing are not perfectly synonymous. A cell can degranulate without successfully killing its target, and the degree of target cell death depends on other factors like the amount of perforin and granzyme released per granule, the distance between killer and target, and whether the target cell has its own resistance mechanisms. CD107a tells you the cell fired its weapon. It does not guarantee the bullet hit. For that reason, many researchers pair the CD107a assay with a direct measure of target cell death, or with staining for intracellular cytokines, to get a fuller functional picture.
The specificity question also matters in certain contexts. Because LAMP-1 is a basic lysosomal protein found in virtually every cell type, elevated LAMP-1 staining does not automatically mean immune degranulation occurred. In non-immune cells, increased LAMP-1 can reflect heightened lysosomal activity, autophagy, or membrane repair. Interpreting LAMP-1 signals always requires knowing which cell type you are looking at and under what conditions the staining was performed.